NCT02788201
|
Phase II |
Erlotinib
Thiotepa
Imatinib
Dacarbazine
Arsenic trioxide
Idarubicin
Mitomycin C
Thioguanine
Mercaptopurine
Methotrexate
Cladribine
epirubicin
Gemcitabine
Doxorubicin
Bleomycin
Etoposide
Gefitinib
Daunorubicin
Lomustine
Sorafenib
Sunitinib
Ifosfamide
Asparaginase
Ixabepilone
Abiraterone
Azacitidine
Ruxolitinib
Decitabine
Axitinib
Estramustine
Floxuridine
Lapatinib
Carmustine
Fludarabine
Nilotinib
Cisplatin
Vismodegib
Vandetanib
Melphalan
Busulfan
Carboplatin
Toremifine
Crizotinib
Dactinomycin
Temsirolimus
Vorinostat
romidepsin
Fluorouracil
Irinotecan
Bortezomib
Tamoxifen
Topotecan
Chlorambucil
Pentostatin
Eribulin
Carfilzomib
Vemurafenib
Hydroxyurea
Exemestane
Vincristine
Dasatinib
Mitoxantrone
Vinblastine
Cytarabine
Tretinoin
Clofarabine
Teniposide
Docetaxel
Pazopanib
Oxaliplatin
Streptozocin
Paclitaxel
Bendamustine
Mechlorethamine
Mitotane
|
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma |
Recruiting |